Rocket Lab's Dual Narrative: Technical Triumphs vs. Financial Strains as Stock Tanks 11%

Despite successful engine test and Space Force mission, Rocket Lab shares drop 11.43% amid $8B Iridium deal concerns, insider selling, and analyst divide.

The market is sending a blunt message about Rocket Lab USA: technical milestones matter less than the bill coming due. Despite a successful full-duration test of the Archimedes vacuum engine on July 13 and the completion of a complex US Space Force mission, shares cratered 11.43% on Thursday to €58.90 — a level that is now 55.98% below the 52-week high of €133.80 reached on May 27. The sell-off has shaved roughly $14 billion in market value since the company announced its $8 billion acquisition of satellite operator Iridium Communications in late June.

That deal is the root cause of the anxiety. Under the terms, Iridium shareholders will receive $27 in cash per share plus Rocket Lab stock at a fixed exchange ratio, implying a total price of about $54 per Iridium share. The cash component — financed with a $3.6 billion bridge loan — has ignited fears of dilution and balance-sheet strain. Rocket Lab's operating margin of minus 33.2% offers little reassurance, even as revenue has grown 45.8% over the trailing twelve months, far outpacing the S&P 500 median of 7.5%.

The operational picture, by contrast, is improving. The VICTUS-HAZE mission for the US Space Force marked the first time Rocket Lab served as sole prime contractor for rocket, satellite, and orbital operations — a milestone that underscores the Pentagon's growing reliance on commercial providers. Days later, the Archimedes vacuum engine for the second stage of the Neutron rocket completed a 5.5-minute full-power test at NASA's Stennis Space Center, clearing a key hurdle for the heavy-lift vehicle's planned debut by late 2026. That timeline, however, already slipped once due to a tank test failure, and the $5.6 billion NSSL Phase 3 Lane 1 contracts that Neutron is designed to capture remain contingent on a successful first flight.

Wall Street is split on what the sum of these parts is worth. Piper Sandler initiated coverage with a Neutral rating and a $83 price target, calling Rocket Lab "the most credible No. 2 behind SpaceX" while arguing that the stock's recent run-up had stretched its valuation. The firm's analyst, Alexander Potter, also initiated coverage of AST SpaceMobile with an Overweight rating and $100 target, identifying a "clearer path to positive EBITDA" in that name. By contrast, Morgan Stanley raised its bull-case price target to $293 from $185 on July 8, maintaining an Overweight rating and a base case of $105, citing the Iridium deal's strategic value: a global satellite network, L-band spectrum, and millions of recurring subscribers that transform Rocket Lab from a pure launch provider into a vertically integrated space platform. The broader consensus, according to MarketBeat, is a Moderate Buy with an average price target of $110.18.

Insider behavior adds another layer of concern. Over the past three months, executives and insiders sold shares worth $362.8 million, with CEO Peter Beck executing a prearranged 10b5-1 plan. No insider has bought shares on the open market in the last six months, according to TradeVae — a pattern that typically signals limited confidence at the top.

Technically, the stock is deeply oversold. The 14-day relative strength index sits at 29.6, and the price has fallen 37.5% below its 50-day moving average of €94.24. The 200-day moving average of €67.32 is still above the current price, though the gap has narrowed. Annualized 30-day volatility has surged to nearly 97%, reflecting frayed nerves among traders. Some analysts attribute part of the weakness to a broader rotation out of high-growth space names, possibly linked to the recent Nasdaq listing of SpaceX — but the overriding driver remains the Iridium financing uncertainty.

Rocket Lab reports second-quarter results on August 6. Analysts expect revenue of $231.79 million and a loss of $0.07 per share. With the Neutron program advancing and the Iridium deal still weighing on sentiment, that earnings call will be the next test of whether operational momentum can outweigh balance-sheet fear.